의학박사 학위논문

No effect of desmopressin administration

before kidney biopsy

on the risk of major post-biopsy bleeding

신장조직검사 전의 desmopressin 투여가

조직검사 후 중한 출혈의 발생에 미치는 영향

울 산 대 학 교 대 학 원

의   학   과

정 민 선

No effect of desmopressin administration

before kidney biopsy

on the risk of major post-biopsy bleeding

지 도 교 수   김 순 배

이 논문을 의학박사 학위 논문으로 제출함

2021 년   2 월

울 산 대 학 교 대 학 원

의   학   과

정 민 선

정민선의 의학박사학위 논문을 인준함

심사위원장	양 원 석	(인)
심사위원	김 순 배	(인)
심사위원	장 재 원	(인)
심사위원	서 장 원	(인)
심사위원	김 효 상	(인)

울 산 대 학 교 대 학 원

2021 년   2 월

Abstract

Background/Aims: Bleeding is the most important complication of a kidney biopsy, and it is unclear whether desmopressin is effective in preventing it. Thus, the study was conducted to compare post-biopsy bleeding with or without desmopressin prescription prior to percutaneous kidney biopsy.

Methods: In this single-centered, retrospective, and observational study, 3,018 adult patients who underwent a kidney biopsy between January 1, 2003 and March 31, 2019 at our institute were recruited. Of these, 776 patients received desmopressin. To compare the differences in major bleeding events between patients administered and not administered with desmopressin, propensity score matching was performed.

Results: Before propensity score (PS) matching, it was observed that patients in the desmopressin group were significantly older ($p < 0.001$) and had a higher blood pressure ($p < 0.001$), higher serum creatinine ($p < 0.001$), lower hemoglobin levels ($p < 0.001$), and lower platelet counts ($p = 0.001$) than those in the no-desmopressin group. The incidence of renal

artery embolization following the kidney biopsy was not significantly different between the

two groups ($p = 0.077$); however, blood transfusions occurred significantly more frequently in

the desmopressin group ($p < 0.001$). A comparison of the two groups after PS matching did

not reveal any differences in the incidence of renal artery embolization ($p = 0.341$), blood

transfusion ($p = 0.579$), and total major bleeding events ($p = 0.442$). Furthermore, there was

no difference in the incidence of perinephric hematoma on computed tomography or

ultrasound ($p = 0.120$).

Conclusions: We do not recommend desmopressin administration before kidney biopsy.

차 례

표 목차

1. Introduction

Percutaneous kidney biopsy is an important modality for diagnosing and treating glomerular disease. Complications in biopsies can be major (those that require interventions such as a blood transfusion or procedure to stop bleeding) and minor (those that do not require special interventions, for e.g., hematuria or perinephric hematoma).[1]

Desmopressin is a long-acting synthetic analog of vasopressin, and was originally designed to treat diabetes insipidus.[2] It is now used to treat bleeding disorders as well, because it can induce an increase in the plasma levels of factor VIII and the von Willebrand factor, thereby shortening the prolonged activated partial thromboplastin time (aPTT) and the bleeding time.[3]

The effect of desmopressin on the risk of post-kidney biopsy bleeding remains controversial (Table 1). Two studies revealed that desmopressin decreased the bleeding risk,[4,5] while one study revealed that it did not decrease the bleeding risk.[6] Two additional studies also reported controversial results.[7,8]

We previously reported that intravenous desmopressin significantly reduced the level of collagen/epinephrine and collagen/adenosine diphosphate closure time in uremic patients.[2] We also reported that a single injection of desmopressin prior to invasive procedures in uremic patients using antiplatelet agents ameliorated platelet dysfunction (measured by *in vitro* collagen/epinephrine occlusion time).[9] Based on these studies, over the past 17 years, we have administered desmopressin to some patients prior to kidney biopsy.

This study was performed to compare major post-biopsy bleeding between patients who were prescribed with desmopressin prior to percutaneous kidney biopsy and patients who were not.

2. Material and methods

2.1 Patients

A retrospective single-center study was conducted to compare the incidence of severe post-kidney biopsy bleeding between adult patients who were administered with desmopressin and patients who were not. Patients who underwent kidney biopsy at our institute from January 1, 2003 to March 31, 2019 were included. The exclusion criteria were as follows: 1) transplanted kidney biopsy (when kidney transplant was performed a day prior to the kidney biopsy or kidney transplant disease codes were available), 2) open kidney biopsy, 3) age < 18 years at the time of kidney biopsy, and 4) mass biopsy for cancer diagnosis. A search using our center's Biomedical Research Environment revealed that 6,877 patients underwent a kidney biopsy during the period specified above. Among these, 6,518 patients were aged 18 years or above. After excluding for transplant kidney biopsy and open kidney biopsy, 4,051 patients were identified; of these, 3,018 patients were selected as the final study subjects. Informed consent for participation in this study was not necessary because the data were collected from clinical practice.

2.2 Data collection

The following data were collected:

1. Desmopressin administration: Yes/No

2. Consumption of anticoagulants or antiplatelet drugs before kidney biopsy: Yes/No

3. Baseline characteristics at the time of kidney biopsy: age, sex, weight, height, and body mass index (BMI)

4. Comorbidities: diabetes mellitus, hypertension

5. Blood pressure just before and after the kidney biopsy

     1) Systolic blood pressure (SBP) (mmHg)

     2) Diastolic blood pressure (DBP) (mmHg)

3) Mean arterial pressure (MAP) (mmHg)

6. Blood and urine test results obtained just before and after the kidney biopsy

1) Hemoglobin (g/dL), platelet ($\times 10^3$/μL), hematocrit (%)

2) Prothrombin time (PT international normalized ratio [INR]), activated partial thromboplastin time (sec)

3) Serum creatinine (mg/dL), estimated glomerular filtration rate (eGFR) (ml/min/1.73 m^2), blood urea nitrogen (BUN) (mg/dL)

4) Spot urine albumin/creatinine ratio (g/g), spot urine protein/creatinine ratio (g/g)

7. Kidney biopsy data

1) Number of needle passes, number of biopsy segments

2) Clinical indication for kidney biopsy

(i) Hematuria and/or non-nephrotic range proteinuria

(ii) Azotemia

(iii) Nephrotic syndrome

3) Histological diagnosis

(i) Glomerulonephritis

(ii) Nephrosclerosis

(iii) Tubulo-interstitial nephritis

(iv) Lupus nephritis

(v) Diabetic nephropathy

(vi) Vasculitis

(vii) Amyloidosis

(viii) Others

4) Department that performed biopsy

(i) Nephrology

(ii) Rheumatology

(iii) Allergy

           (iv) Others

8. Bleeding events

    1) Renal artery embolization

    2) Blood transfusion (limited to red blood cell transfusion)

    3) Perinephric hematoma on computed tomography (CT) or ultrasound (US), Size of the hematoma

    4) Nephrectomy due to bleeding

    5) Length of hospital stay

The eGFR presented in our electronic medical record was estimated using the modification of diet in renal disease (MDRD) equation (MDRD eGFR) and the chronic kidney disease epidemiology collaboration (CKD-EPI) equation (CKD eGFR). We have selected and applied MDRD eGFR.

In order to identify bleeding events, cases where renal artery embolization and blood transfusion were performed within 7 days from the biopsy were investigated. Furthermore, in cases where CT or US was performed within 7 days from the biopsy, the presence of perinephric hematoma was investigated. Hematoma size data were included only when it was described in the official reading. The major bleeding events were defined as cases that underwent blood transfusion and renal artery embolization.

2.3 Biopsy procedure and desmopressin administration

In all kidney biopsies, patients were provided with a detailed explanation of the protocol and informed consent was obtained. Prior to the procedure, the patient's complete blood count (CBC) and coagulation profile were checked. Transfusions were recommended for patients with hemoglobin levels lower than 10 g/dL or with platelet counts lower than 100,000/μL. Patients who consumed anticoagulants or antiplatelet drugs prior to kidney biopsy underwent a period of discontinuation. Furthermore, aspirin and clopidogrel consumption was skipped for 7 days, cilostazol for 3 days, and warfarin until the PT INR was normal.

There was no standardized hospital protocol for the administration of desmopressin in this study. Desmopressin was administered to subjects who were deemed to have a high risk of bleeding by the attending physician; these subjects were typically those with a known high risk of bleeding, i.e., patients with impaired renal function and elevated BUN, old age, high blood pressure, low hemoglobin levels, and low platelet counts. Patients in the desmopressin group received a dose of 0.3 µg/kg desmopressin (Minirin®, Ferring, Saint-Prex, Switzerland) in 100 cc normal saline 30 minutes before the procedure.

A 16- or 18-gauge semiautomated, side-notch disposable biopsy needle was used for the biopsy (STARCUT®, TSK Laboratory, Tochigi, Japan). To reduce the risk of bleeding, 18-gauge needles (9–12 cm in length) were used in most cases.[10] By using needles of a gauge thinner than that of the usual ones, the risk of bleeding was reduced. Therefore, even in patients with a relatively high bleeding tendency, punctures were repeated several times to obtain sufficient tissue. For native kidney biopsy, we aimed to collect more than 25 glomeruli and obtain an average of about three segments. The biopsies were conducted using real-time ultrasound guidance. After the procedure, a sandbag was placed on the biopsy site for 3 hours and the patient rested in a supine position. Then, after being transferred to the ward, the blood pressure and pulse rate were measured periodically, and the CBC was checked the next morning. If vital signs became unstable or other bleeding complications, such as gross hematuria or severe abdominal pain, were detected, CT or US was performed and renal artery embolization and blood transfusion were undertaken as required. CT or US was not performed routinely after kidney biopsy in patients without any symptoms.

2.4 Ethics statements

This study was conducted in accordance with the ethical standards of the Declaration of Helsinki (as revised in Brazil, 2013). This research protocol was approved by the Institutional Review Board of our institute (No. 2019-0427).

2.5 Statistical analysis

The numerical data were expressed as mean ± standard deviation, and a Student's t-test was performed to compare the means of the two independent groups. The chi-square test and Fisher's exact test were performed to compare categorical data between the two groups. The frequency of occurrence was expressed as a percentage (%). To compare the difference according to whether desmopressin was administered or not, propensity score matching (PS matching) was performed. After performing multiple imputations, the average of PSs estimated from each completed dataset was used. In case of a 2:1 or 3:1 matching, several patients in the desmopressin group were lost; thus, a 1:1 matching was performed. Post-matching outcome comparison was performed using logistic regression, with correlation allowed within the matching pair and a robust estimator. PS matching was performed using the R software, version 3.6.1, while the remaining tests were performed using IBM SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, N.Y., USA). In addition, $p < 0.05$ was considered statistically significant.

3. Results

3.1 Comparison of baseline characteristics before kidney biopsy

There were no significant differences in the weight, height, and BMI between the two groups; however, the age was significantly higher in the desmopressin group than in the no-desmopressin group ($p < 0.001$). Furthermore, the SBP, DBP, and MAP were also significantly higher in the desmopressin group than in the no-desmopressin group ($p < 0.001$). The hemoglobin, platelet, and hematocrit levels were significantly lower in the desmopressin group than in the no-desmopressin group ($p < 0.001$, $p = 0.001$, and $p < 0.001$, respectively). The PT ($p < 0.001$) and aPTT ($p = 0.025$) were significantly higher in the desmopressin group than in the no-desmopressin group. Serum creatinine and BUN were significantly higher ($p < 0.001$), while eGFR was significantly lower ($p < 0.001$) in the desmopressin group than in the no-desmopressin group. The urine protein/creatinine ratio ($p = 0.007$) was also significantly higher in the desmopressin group than in the no-desmopressin group. The use of anticoagulants or antiplatelet drugs before renal biopsy was significantly more in the desmopressin group as compared to in the no-desmopressin group ($p < 0.001$) (Table 2).

3.2 Comparison of kidney biopsy indications and results

The incidence of clinical indications for kidney biopsy were significantly different between the desmopressin and no-desmopressin groups ($p < 0.001$). Hematuria and/or non-nephrotic range proteinuria (54.3% in the desmopressin group, 67.2% in the no-desmopressin group) were the most common indications. The incidence of azotemia as an indication was higher in the desmopressin group than in the no-desmopressin group (36.3% vs. 13.4%), while the incidence of nephrotic syndrome as an indication was higher in the no-desmopressin group than in the desmopressin group (19.4% vs. 9.4%). The histological diagnosis also differed between the two groups ($p < 0.001$): Glomerulonephritis was the most common (66.8% in the desmopressin group, 58.3% in the no-desmopressin group), while lupus nephritis was more common in the no-desmopressin group (14.9% vs. 6.1%). The departments where

the biopsy was performed differed significantly between the two groups ($p < 0.001$); however, the nephrology department was the most common in both groups (87.0% in the desmopressin group, 76.8% in the no-desmopressin group) (Table 2).

3.3 Bleeding events within 7 days before PS matching

The incidence of renal artery embolization did not differ significantly between the two groups ($p = 0.077$); however, blood transfusions occurred significantly more frequently in the desmopressin group than in the no-desmopressin group ($p < 0.001$). The frequency of perinephric hematoma (detected by CT and US) was significantly higher in the desmopressin group than in the no-desmopressin group ($p < 0.001$). In both groups, there was no case in which nephrectomy was performed due to complications from renal biopsy. After biopsy, hemoglobin levels were significantly lower in the desmopressin group than in the no-desmopressin group ($p < 0.001$); moreover, hemoglobin reduction was significantly higher in the desmopressin group ($p < 0.001$). The size of the hematoma was significantly larger in the desmopressin group as compared to in the no-desmopressin group ($p = 0.016$). Post-biopsy SBP ($p < 0.001$) and MAP ($p = 0.002$) were higher in the desmopressin group than in the no-desmopressin group; moreover, the reduction in SBP was significantly greater in the desmopressin group ($p = 0.007$). Hospital stay was significantly longer in the desmopressin group than in the no-desmopressin group ($p < 0.001$) (Table 3).

3.4 Comparison of bleeding events after PS matching

The age, sex, BMI, SBP, MBP, hemoglobin, platelet count, hematocrit, PT, aPTT, serum creatinine, eGFR, and BUN were chosen as variables that could influence bleeding events. Following PS matching for these variables, there were no differences in the variables between the two groups, as the standardized mean difference (SMD) was less than 0.1 (Table 4).

Comparison of the two adjusted groups revealed no intergroup differences in the incidence of renal artery embolization ($p = 0.341$), blood transfusion ($p = 0.579$), and total major bleeding events ($p = 0.442$). Furthermore, total bleeding events (including perinephric hematoma on CT/US) did not differ

between the two groups ($p = 0.239$) (Table 5).

The degree of serum sodium reduction was significantly greater in the desmopressin group than in the no-desmopressin group by an average of 1.92 ($p < 0.001$). Furthermore, the incidence of significant hyponatremia of less than 125 mmol/L was significantly higher in the desmopressin group than in the no-desmopressin group ($p = 0.008$) (Table 5).

3.5 Subgroup analysis on matched data for major bleeding events

Comparison of the two groups based on a creatinine level of 1.8 mg/dL revealed that desmopressin did not significantly change the major bleeding risk in both groups ($p = 0.808$ for serum creatinine less than 1.8 mg/dL, $p = 0.482$ for more than 1.8 mg/dL, and $p = 0.870$ indicating the difference between the two groups). In addition, there was no difference in the incidence of bleeding according to the administration of desmopressin even when sex was classified and compared at each creatinine level (Table 6).

4. Discussion

This is the largest study to investigate the effect of desmopressin on major bleeding risk (requiring renal artery embolization and blood transfusion) following kidney biopsy. To investigate the major bleeding events, of the 3,018 patients analyzed, 776 and 2,242 were categorized into the desmopressin and no-desmopressin groups, respectively. After adjusting the two groups by PS matching, we concluded that there was no difference in the major bleeding risk after desmopressin administration. Regarding major post-biopsy bleeding, Peters et al.[5] reported that multiple logistic regression revealed that prophylaxis using desmopressin prior to native kidney biopsy led to lesser major complications (for example, bleeding, acute hydronephrosis, and septicemia that requires transfusion and/or an invasive intervention; odds ratio [OR]: 0.38). Furthermore, Leclerc et al.[8] reported that patients who received desmopressin had a likelihood of symptomatic hematomas similar to those who did not (OR: 0.39) and a need for urgent radiologic studies lower than those who did not (OR: 0.33). Regarding minor post-biopsy bleeding in this study, there was no difference in the incidence of perinephric hematoma on CT or US between the two groups ($p = 0.120$)

The Caring for Australians with Renal Impairment (CARI) guidelines (2018) recommended that as there is a lack of evidence to support the benefit or harm of desmopressin administration prior to renal biopsy, care units should continue their existing practice until a higher level of evidence is available.[11] In 2011, Whittier suggested that although desmopressin may play a role in patients at a high risk of bleeding (which deserves a study in itself), administering desmopressin off-label to all patients undergoing percutaneous kidney biopsy is premature and possibly hazardous.[1] In this study as well, we observed a greater sodium reduction in the desmopressin group than that observed in the no-desmopressin group. Considering the increased risk of thrombotic events or hyponatremia associated with desmopressin use,[11] we do not recommend desmopressin use before kidney biopsy.

Previous studies reported that the serum creatinine, blood pressure, age, gender, hemoglobin, and platelet count were the risk factors of bleeding after kidney biopsy. In a study by Corapi et al.[10]

that compared and analyzed 34 studies through meta-analysis of bleeding complications of native kidney biopsy, the transfusion rate was significantly higher in women ($\geq$ 50%) ($p = 0.03$) and when the mean serum creatinine level was ≥ 2.0 mg/dL ($p = 0.02$). Furthermore, although age ≥ 40 years ($p = 0.2$) and mean SBP ≥ 130 mmHg ($p = 0.09$) were not significant risk factors, they were associated with a tendency for high transfusion requirements. Moreover, Xu et al.[12] also reported that a low platelet count significantly increased the risk of severe bleeding after renal biopsy. In our study, compared to the no-desmopressin group, the desmopressin group was older and had a higher blood pressure and serum creatinine level and lower hemoglobin and platelet levels. As a result, blood transfusions were significantly more common in the desmopressin group before PS matching. A striking observation was the higher number of transfusions in the desmopressin group than in the no-desmopressin group (11% vs. 2.8%) with an average hemoglobin reduction of 0.79 ± 0.99 g/dL and a mean post-biopsy hemoglobin level of 10.5 g/dL.

Therefore, PS matching was performed to reduce selection bias and compare the bleeding events in the two groups. The SMD[13, 14] was calculated by comparing all variables deemed to affect bleeding, and was found to be less than 0.1 after correction. Because there were some variables with many missing values, we performed multiple imputations and used the average of PSs from all completed data sets. Because there were fewer patients in the desmopressin group, after matching, the two groups were organized based on those who had the potential to receive desmopressin, and reflected the "average treatment effect on the treated patients" rather than the "average treatment effect" (Table 4). On comparing the bleeding events between the two adjusted groups, no intergroup differences were noted in the incidence of both, renal artery embolization and blood transfusion.

The major limitation of this study is its retrospective and observational nature, which may have inherent selection bias. In our hospital, there was no protocol for administering desmopressin; therefore, desmopressin was administered to people at a high risk of bleeding, as judged by the attending physician. Furthermore, the predominant use of small caliber needles in a generalized way (usually 18-gauge) or a large number of punctures (4 passes and 3.7 passes) could be confounders and influence the absence of differences between the desmopressin and no-desmopressin groups.

5. Conclusions

We do not recommend desmopressin administration before kidney biopsy.

References

1. Whittier WL. Percutaneous kidney biopsy: "the needle and the damage done"? [Editorial]. Am J Kidney Dis. 2011;57(6):808-10.

2. Lee HK, Kim YJ, Jeong JU, Park JS, Chi HS, Kim SB. Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients. Nephron Clin Pract. 2010;114(4):c248-c52.

3. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years [Review article]. Blood. 1997;90(7):2515-21.

4. Manno C, Bonifati C, Torres DD, Campobasso N, Schena FP. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis. 2011;57(6):850-5.

5. Peters B, Hadimeri H, Mölne J, Nasic S, Jensen G, Stegmayr B. Desmopressin (Octostim®) before a native kidney biopsy can reduce the risk for biopsy complications in patients with impaired renal function: a pilot study. Nephrology (Carlton). 2018;23(4):366-70.

6. Radhakrishnan S, Chanchlani R, Connolly B, Langlois V. Pre-procedure desmopressin acetate to reduce bleeding in renal failure: does it really work? Nephron Clin Pract. 2014;128(1-2):45-8.

7. Athavale A, Kulkarni H, Arslan CD, Hart P. Desmopressin and bleeding risk after percutaneous kidney biopsy. BMC nephrol. 2019;20(1):413.

8. Leclerc S, Nadeau-Fredette A-C, Elftouh N, Lafrance J-P, Pichette V, Laurin L-P. Use of desmopressin prior to kidney biopsy in patients with high bleeding risk. Kidney Int Rep. 2020;5(8):1180-7.

9. Kim JH, Baek CH, Min JY, Kim J-S, Kim SB, Kim H. Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Ann Hematol. 2015;94(9):1457-61.

10. Corapi KM, Chen JL, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60(1):62-73.

11. MacGinley R, Champion De Crespigny PJ, Gutman T, Lopez-Vargas P, Manera K, Menahem S, et al. KHA-CARI guideline recommendations for renal biopsy. Nephrology (Carlton). 2019;24(12):1205-13.

12. Xu D-m, Chen M, Zhou F-d, Zhao M-h. Risk factors for severe bleeding complications in percutaneous renal biopsy. Am J Med Sci. 2017;353(3):230-5.

13. Flury BK, Riedwyl H. Standard distance in univariate and multivariate analysis. Am Stat. 1986;40(3):249-51.

14. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228-34.

국문요약

배경: 신장 조직 검사의 가장 중요한 합병증은 출혈이며, desmopressin이 이를 예방하는 데 효과적인지 여부는 불분명하다. 이 연구는 경피적 신장 조직 검사 전 desmopressin 투약 여부에 따른 조직 검사 후에 발생한 출혈을 비교하기 위해 수행되었다.

방법: 2003년 1월 1일부터 2019년 3월 31일까지 서울아산병원에서 신장 조직 검사를 받은 3,018명의 성인 환자를 대상으로 단일 기관 후향적 관찰 연구를 수행하였다. 3,018명 중 776명의 환자가 desmopressin을 투여 받았다. Desmopressin을 투여한 환자와 투여하지 않은 환자의 출혈 경향을 비교하기 위해 성향점수매칭 (propensity score matching)을 수행하였다.

결과: 성향점수매칭을 시행하기 전에는 desmopressin 그룹이 desmopressin을 투여하지 않은 그룹에 비해 유의하게 나이가 많고 ($p < 0.001$) 혈압이 높고 ($p < 0.001$) 혈청 크레아티닌이 높고 ($p < 0.001$) 헤모글로빈 수치가 낮고 ($p < 0.001$) 혈소판 수가 적었다 ($p = 0.001$). 또한, 신동맥 색전술의 발생률은 두 그룹 간에 유의한 차이가 없었으며 ($p = 0.077$) 수혈은 desmopressin 그룹에서 유의하게 더 자주 발생하였다 ($p < 0.001$). 하지만 성향점수매칭 후 두 그룹을 비교한 결과 신동맥 색전술 ($p = 0.341$), 수혈 ($p = 0.579$), 총 주요 출혈 사건(신동맥 색전술 + 수혈) ($p = 0.442$)의 발생률에 차이가 없었다. 또한 컴퓨터 단층 촬영이나 초음파에서 발견되는 신장주위 혈종의 발생률에도 차이가 없었다 ($p = 0.120$).

결론: 신장 조직 검사 전에 desmopressin 투여를 권장하지 않는다.

중심 단어: Desmopressin, 신장 조직 검사, 신동맥 색전술, 수혈, 신장주위 혈종, 성향점수매칭

Table 1. Summary of studies on the effects of desmopressin on post-kidney biopsy bleeding

Study ID	Number of patients	Study design	Desmopressin dose (µg/kg)	Needle diameter (gauge)	Results
Manno et al.[4] (2011)	162 patients undergoing native kidney biopsy	Randomized, controlled, single-center study; Italy	0.3 (SC)	16	Desmopressin significantly decreased post-biopsy bleeding (13.7% vs. 30.5%, $p = 0.01$).
Radhakrishnan et al.[6] (2014)	43 patients (22 with native kidney biopsy and 21 with central line placement)	Retrospective single-center study; Canada	0.3 (IV)	18	No difference in the bleeding complications between desmopressin and no-desmopressin groups (23% vs. 27%, $p = 1.0$).
Peters et al.[5] (2018)	576 patients with serum creatinine above 150 µmol/L ($\geq$ 1.7 mg/dl) undergoing native kidney biopsy	Most prospective multicenter study; Sweden	0.3 (SC)	16, 18	Multiple logistic regression revealed that desmopressin showed lesser major (OR: 0.38) and overall complications (OR: 0.36).
Athavale et al.[7] (2019)	269 patients undergoing percutaneous kidney biopsy	Retrospective single-center study; United States of America	0.3 (IV)	18	Desmopressin decreased bleeding risk in patients with serum creatinine $\geq$ 1.8 mg/dL (OR: 2.11, $p = 0.09$), but increased the risk when serum creatinine was < 1.8 mg/dL (OR: 9.72, $p < 0.001$).
Leclerc et al.[8] (2020)	413 patients undergoing native kidney biopsies	Retrospective single-center study; Canada	0.3 (IV)	16 (98%), 18	Despite a higher bleeding risk, patients using desmopressin had a similar likelihood of symptomatic hematomas (OR: 0.39) and a lower need for urgent radiologic studies (OR: 0.33).
Cheong et al.	3,018 patients undergoing native kidney biopsy	Retrospective single-center study; South Korea	0.3 (IV)	16, 18 (most)	No differences in the incidence of renal artery embolization ($p = 0.341$), blood transfusion ($p = 0.579$), and total major bleeding events ($p = 0.442$).

Table 2. Baseline characteristics before kidney biopsy and kidney biopsy information

	Desmopressin group N = 776 (25.7%)	No-desmopressin group N = 2,242 (74.3%)	p
Age (years)	50.2 ± 16.8	43.5 ± 16.1	<0.001
Men/women (Women %)	432/344 (44.3%)	1087/1155 (51.5%)	0.001
Weight (kg)	64.2 ± 12.6	64.1 ± 13.0	0.869
Height (cm)	163.9 ± 8.9	163.7 ± 9.1	0.690
Body mass index (kg/m^2)	23.9 ± 3.6	23.8 ± 3.8	0.581
Systolic blood pressure (mmHg)	126 ± 19	121 ± 17	<0.001
Diastolic blood pressure (mmHg)	79.6 ± 11.7	77.3 ± 10.8	<0.001
Mean arterial pressure (mmHg)	95.1 ± 12.9	91.9 ± 11.9	<0.001
Blood parameters			
Hemoglobin (g/dL)	11.3 ± 2.6	12.6 ± 2.3	<0.001
Platelet (×10^3/μL)	243 ± 93	256 ± 82	0.001
Hematocrit (%)	33.7 ± 7.4	37.7 ± 6.4	<0.001
Prothrombin time (INR)	1.02 ± 0.11	0.98 ± 0.09	<0.001
aPTT (sec)	29.2 ± 5.8	28.6 ± 4.3	0.025
Serum creatinine (mg/dL)	2.87 ± 2.68	1.24 ± 1.25	<0.001
eGFR (ml/min/1.73 m^2)	45.0 ± 34.5	73.6 ± 28.2	<0.001
BUN (mg/dL)	33.5 ± 22.9	19.3 ± 13.1	<0.001
Spot urine tests			
Urine albumin/creatinine ratio (g/g)	1.8 (0.5, 4.5)	1.5 (0.5, 3.9)	0.161
Urine protein/creatinine ratio (g/g)	2.4 (1.0, 5.8)	1.7 (0.7, 4.1)	0.007
Comorbidities			
Diabetes mellitus	202 (26.0%)	233 (10.4%)	<0.001
Hypertension	315 (40.6%)	637 (28.4%)	<0.001
Anticoagulant/antiplatelet use before biopsy	264 (34.0%)	601 (26.8%)	<0.001
Number of needle passes	4.08 ± 1.11	3.73 ± 1.09	<0.001
Number of biopsy segments	3.33 ± 0.82	3.20 ± 0.80	0.003
Clinical indication for kidney biopsy			<0.001
Hematuria and/or non-nephrotic range proteinuria	421 (54.3%)	1507 (67.2%)	
Azotemia	282 (36.3%)	300 (13.4%)	
Nephrotic syndrome	73 (9.4%)	435 (19.4%)	
Histologic diagnosis			<0.001
Glomerulonephritis	518 (66.8%)	1307 (58.3%)	
Nephrosclerosis	16 (2.1%)	34 (1.5%)	
Tubulo-interstitial nephritis	50 (6.4%)	67 (3.0%)	
Lupus nephritis	47 (6.1%)	334 (14.9%)	
Diabetic nephropathy	24 (3.1%)	101 (4.5%)	
Vasculitis	40 (5.2%)	99 (4.4%)	
Amyloidosis	8 (1.0%)	33 (1.5%)	
Others	73 (9.4%)	267 (11.9%)	

Department that performed the biopsy			<0.001
Nephrology	675 (87.0%)	1722 (76.8%)	
Rheumatology	42 (5.4%)	157 (7.0%)	
Allergy	7 (0.9%)	140 (6.2%)	
Others	52 (6.7%)	223 (9.9%)	

Note: Data are expressed as mean±standard deviation, medians (25th and 75th percentile), or absolute frequencies and percentiles. aPTT, activated partial thromboplastin time; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen

Table 3. Bleeding events within 7 days

	Desmopressin group N = 776 (25.7%)	No-desmopressin group N = 2,242 (74.3%)	OR (95% CI)	*p*
Bleeding events				
Renal artery embolization	4 (0.5%)	3 (0.1%)	3.87 (0.86, 17.32)	0.077
Blood transfusion	85 (11.0%)	63(2.8%)	4.26 (3.04, 5.96)	<0.001
Perinephric hematoma on CT	34 (4.4%)	36 (1.6%)	2.81 (1.74, 4.52)	<0.001
Perinephric hematoma on US	13 (1.7%)	4 (0.2%)	9.53 (3.10, 29.32)	<0.001
Perinephric hematoma (total)	42 (5.4%)	39 (1.7%)	3.23 (2.07, 5.04)	<0.001
Hemoglobin after biopsy (g/dL)[*]	10.5 ± 2.3	12.5 ± 2.3		<0.001
Hemoglobin reduction (g/dL)	0.79 ± 0.99	0.17 ± 0.89		<0.001
Size of hematoma (mm)[†]	32.0 ± 14.0 (N=16)	18.2 ± 15.9 (N=15)		0.016
Post-biopsy blood pressure[‡]				
SBP after biopsy (mmHg)	120 ± 18	116 ± 16		<0.001
DBP after biopsy (mmHg)	74.2 ± 11.3	73.4 ± 10.3		0.116
MAP after biopsy (mmHg)	89.3 ± 12.4	87.8 ± 11.4		0.002
SBP reduction (mmHg)	6.34 ± 16.24	4.53 ± 14.54		0.007
Length of hospital stay (day)	10.5 ± 15.2	6.4 ± 11.1		<0.001

OR, odds ratio; CI, confidence interval; CT, computed tomography; US, ultrasound; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure

[*]first blood test after kidney biopsy; [†]maximal thickness, [‡]first blood pressure after kidney biopsy

Table 4. Propensity score matching for comparison of differences according to whether desmopressin was administered or not

	Before matching Desmopressin		*p*	SMD	After matching Desmopressin		SMD
	(+)	(-)			(+)	(-)	
Number of patients	776	2242			627	627	
Age (years)	50.2 ± 16.8	43.5 ± 16.1	<0.001	0.405	49.0 ± 16.7	49.2 ± 16.0	0.014
Women (%)	344 (44.3%)	1155 (51.5%)	0.001	0.144	290 (46.3%)	297 (47.4%)	0.022
Body mass index (kg/m²)	23.9 ± 3.6	23.8 ± 3.8	0.581	0.024	24.1 ± 3.7	23.9 ± 3.9	0.044
Systolic blood pressure (mmHg)	126 ± 19	121 ± 17	<0.001	0.286	124 ± 19	123 ± 18	0.095
Mean arterial pressure (mmHg)	95.1 ± 12.9	91.9 ± 11.9	<0.001	0.260	94.2 ± 12.8	93.2 ± 12.4	0.076
Hemoglobin (g/dL)	11.3 ± 2.6	12.6 ± 2.3	<0.001	0.543	11.8 ± 2.6	11.8 ± 2.5	0.009
Platelet (×10³/μL)	243 ± 93	256 ± 82	0.001	0.144	247 ± 91	247 ± 84	0.001
Hematocrit (%)	33.7 ± 7.4	37.7 ± 6.4	<0.001	0.576	35.1 ± 7.2	35.2 ± 7.0	0.006
Prothrombin time (INR)	1.02 ± 0.11	0.98 ± 0.09	<0.001	0.349	1.00 ± 0.10	1.00 ± 0.09	0.003
aPTT (sec)	29.2 ± 5.8	28.6 ± 4.3	0.025	0.104	29.0 ± 6.1	28.7 ± 4.7	0.040
Serum creatinine (mg/dL)	2.87 ± 2.68	1.24 ± 1.25	<0.001	0.782	2.10 ± 1.93	2.10 ± 2.06	0.002
eGFR (ml/min/1.73 m²)	45.0 ± 34.5	73.6 ± 28.2	<0.001	0.907	53.0 ± 33.6	54.6 ± 31.6	0.046
BUN (mg/dL)	33.5 ± 22.9	19.3 ± 13.1	<0.001	0.765	28.5 ± 20.2	28.4 ± 19.3	0.002

SMD, standardized mean difference; INR, international normalized ratio; aPTT, activated partial thromboplastin time; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen

Table 5. Outcome comparison after propensity score matching

	Desmopressin		OR (95% CI)	*p*
	(+)	(-)		
Number of patients	627	627		
Renal artery embolization (%)	3 (0.5%)	1 (0.2%)	3.01 (0.31, 29.01)	0.341
Blood transfusion (%)	46 (7.3%)	41 (6.5%)	1.13 (0.73, 1.75)	0.579
→ Total major bleeding (%)	48 (7.7%)	41 (6.5%)	1.19 (0.77, 1.83)	0.442
Perinephric hematoma on CT/US (%)	26 (4.1%)	16 (2.6%)	1.65 (0.88, 3.11)	0.120
→ Total bleeding events (%)	63 (10.0%)	51 (8.1%)	1.26 (0.86, 1.86)	0.239
Serum sodium reduction (mmol/L)	3.83 ± 4.33	1.91 ± 3.79	1.92* (1.45, 2.40)	<0.001
Significant hyponatremia (<125 mmol/L) (%)	34 (6.0%)	15 (2.7%)	2.33 (1.25, 4.32)	0.008

OR, odds ratio; CI, confidence interval; CT, computed tomography; US, ultrasound
* Beta (difference in mean)

Table 6. Subgroup analysis of matched data for major bleeding events

	Levels	Number of Patients	Desmopressin OR (95% CI)	p	p for interaction
Serum creatinine (mg/dL)	< 1.8	771	1.11 (0.48, 2.54)	0.808	0.870
	≥ 1.8	483	1.21 (0.72, 2.03)	0.482	
Serum creatinine (mg/dL)	< 1.8 Female	388	1.02 (0.42, 2.51)	0.962	0.603 (< 1.8 Female vs. < 1.8 Male)
	< 1.8 Male	383	2.02 (0.18, 22.48)	0.567	0.889 (< 1.8 Female vs. ≥ 1.8 Female)
	≥ 1.8 Female	199	1.11 (0.54, 2.27)	0.777	0.618 (< 1.8 Female vs. ≥ 1.8 Male)
	≥ 1.8 Male	284	1.38 (0.64, 3.01)	0.414	

OR, odds ratio; CI, confidence